Checked.be
Active
BE 0647.921.990Private limited company
MDL Halet
Etting 18 ·2910 Essen, Belgium· 15 yrs active
Sector: Specialist medical practice
(86220)
Conclusion
MDL Halet has been active since 2011 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €555k and a net result of €75k. Equity is growing by ~16.8% per year across the filed fiscal years. Its solvency ranks better than 84% of 90 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Based on the State Gazette, CBE and 4 annual accounts.
Key figures
| Equity | €555k |
| Net result | €75k |
| Staff (FTE) | 0.2 |
| Better than sector | 84% |
Financial profile
82
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
93
Profitability
67
Solvency
100
Growth
52
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Established
Founded in 2011, 15 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
93
/ 100
Excellent
Computed from 4 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€50k
estimate, not credit advice
Score history
85
2022
85
2023
78
2024
93
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 13.03 (≥ 1.5)
+10
Quick ratio
Quick ratio 13.03 (≥ 1.0)
+5
Leverage
Debt/equity 0.09 (< 1.0)
+10
Profitability
ROE 13% (≥ 10%)
+10
Profit trend
Net profit up YoY
+5
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 28-08-2026 with the NBB · fiscal year 2025 · abbreviated schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~16.8%/year over 4 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (abbreviated schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 91.8% | 56.8% | |
| Net result | €75k | €93k | |
| Equity | €555k | €202k | |
| Gross operating margin | €109k | €237k | |
| Staff costs | €28k | €98k |
€75k
+72.0%
22-25
€605k
+13.9%
22-25
€555k
+15.6%
22-25
€542k
+16.0%
22-25
0
0.0%
22-25
€28k
0.0%
22-25
€15k
+39.6%
22-25
€50k
-1.9%
22-25
€45k
-2.1%
22-25
13.03
+16.8%
22-25
13.03
+16.8%
22-25
91.8%
+1.5%
22-25
0.09
-15.1%
22-25
13.5%
+48.8%
22-25
12.4%
+51.0%
22-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | abbreviated schema | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - | - |
| EBITDA | - | - | - | - |
| Net profit | €75k | €44k | €120k | €121k |
| Cash flow | - | - | - | - |
| Staff costs | €28k | €28k | €26k | - |
| Income taxes | €15k | €11k | €28k | €22k |
| Dividends | - | - | - | - |
| Total assets | €605k | €531k | €470k | €398k |
| Equity | €555k | €480k | €437k | €317k |
| Debt | €50k | €51k | €33k | €80k |
| of which ≤ 1y | €45k | €46k | €29k | €75k |
| of which > 1y | - | - | - | - |
| Working capital | €542k | €467k | €426k | €307k |
| Employees (FTE) | 0.2 | 0.2 | 0.2 | 0.2 |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 13.03 | 11.16 | 15.79 | 5.09 |
| Quick ratio | 13.03 | 11.16 | 15.79 | 5.09 |
| Working capital ratio | 89.6% | 88.0% | 90.5% | 77.2% |
| Solvency | 91.8% | 90.5% | 92.9% | 79.8% |
| Debt / equity | 0.09 | 0.11 | 0.08 | 0.25 |
| Long-term debt ratio | - | - | - | - |
| Interest coverage | - | - | - | - |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 12.4% | 8.2% | 25.5% | 30.4% |
| ROE | 13.5% | 9.1% | 27.4% | 38.1% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (20 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €605k | €531k | €470k | €398k |
| Fixed assets | 21/28 | €18k | €18k | €16k | €16k |
| Financial fixed assets | 28 | €18k | €18k | €16k | €16k |
| Current assets | 29/58 | €587k | €513k | €455k | €382k |
| Amounts receivable within one year | 40/41 | €180k | €142k | €129k | €106k |
| Cash & bank | 54/58 | €187k | €151k | €105k | €55k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €605k | €531k | €470k | €398k |
| Equity | 10/15 | €555k | €480k | €437k | €317k |
| Contributions / capital | 10/11 | €18k | €18k | €18k | €18k |
| Reserves | 13 | €537k | €462k | €419k | €299k |
| Amounts payable | 17/49 | €50k | €51k | €33k | €80k |
| Amounts payable within one year | 42/48 | €45k | €46k | €29k | €75k |
| Income statement | |||||
| Gross operating margin | 9900 | €109k | €74k | €170k | €139k |
| Operating result | 9901 | €81k | €46k | €142k | €139k |
| Financial income | 75 | €13k | €14k | €9k | €6k |
| Financial charges | 65 | €4k | €5k | €3k | €2k |
| Result before taxes | 9903 | €90k | €55k | €148k | €142k |
| Income taxes | 67/77 | €15k | €11k | €28k | €22k |
| Net result for the period | 9904 | €75k | €44k | €120k | €121k |
| Result to be appropriated | 9905 | €75k | €44k | €120k | €121k |
Legal Structure
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 12-04-2011 |
| Status | Active |
| Postal code | 2910 |
Establishment units
MDL Halet B.V.
since 20222.340.799.149
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11642D0129/00N002 | Flanders | 655 m² | 1 · 122 m² | 9.2 m · 2 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
28-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 28 days late
2025
31-12
Financial
Equity above €500kEq €555k ▲15.6%
4 profitable years in a row build equity to €555k.
31-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Weakest financial yearnet €44k ▼63.6%
Net result drops to €44k, the lowest in the series; recovery starts the following year.
22-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Liquidity triplescurrent ratio 15.79
Current ratio from 5.09 to 15.79; short-term debt falls from €75k to €29k.
31-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Specialist medical practice86220
Names & trade names
| Legal name | MDL Halet |
Similar companies
Dr Tina Vanderheyden
BE 0871.377.328 · Antwerpen
Dr.RAMZI HARAKÉ,orthopedie
BE 0502.426.148 · Hasselt
Dr. Jo DUCHATEAU
BE 0894.823.218 · Lier
VW MEDIC
BE 0717.749.223 · Gerpinnes
VINCENT MUSTIN, ORL
BE 0480.121.789 · Elsene